Objective. To describe the clinical, laboratory, radiologic, and histopathologic features of
methotrexate (MTX)‐induced lung injury in a combined cohort of selected patients with …

Methotrexate (MTX) is now the most popular drug worldwide for the treatment of rheumatoid
arthritis. Low-dose, weekly MTX (10 to 25 mg/wk) used as either monotherapy or in …

As in previous years, the consensus group to consider the use of biological agents was
constituted by rheumatologists from the universities of Erlangen, Leiden and Vienna in …

Population stratification—allele frequency differences between cases and controls due to
systematic ancestry differences—can cause spurious associations in disease studies. We …

Objective. Trials of rheumatoid arthritis (RA) treatments report the average response in
multiple outcome measures for treated patients. It is more clinically relevant to test whether …

Objective To develop updated guidelines for the pharmacologic management of rheumatoid
arthritis. Methods We developed clinically relevant population, intervention, comparator, and …

Background Patients treated with methotrexate for rheumatoid arthritis often improve but
continue to have active disease. This study was undertaken to determine whether the …

Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]: Fc fusion protein) safely produced rapid, dose-dependent improvement in …

Objective To evaluate the efficacy and safety of adalimumab (D2E7), a fully human
monoclonal tumor necrosis factor α antibody, in combination with methotrexate (MTX) in …

Objective. To develop a set of disease activity measures for use in rheumatoid arthritis (RA)
clinical trials, as well as to recommend specific methods for assessing each outcome …